A Medical Device Daily

Aethlon Medical (San Diego) a pioneer in developing therapeutic devices for infectious disease, reported yesterday that it has filed a provisional patent submission titled, “Method and Apparatus for Increasing Contaminant Clearance Rates during Extracorporeal Fluid Treatment,” with the U.S. Patent and Trademark Office.

The patent describes technical improvements to the Aethlon Hemopurifier that increase the rate of capture of undesirable blood contaminants including viruses, toxins and immunosuppressive particles associated with cancer.

“Our research team has improved the capability of our Hemopurifier to remove contaminants from the blood,” said James Joyce, CEO and chairman. “The related patent submission reflects an ongoing strategy to protect our developments and further increase the breadth of our intellectual property estate.”

Aethlon Medical is the developer of the Hemopurifier, a medical device designed to treat infectious disease. The Hemopurifier provides real-time therapeutic filtration of infectious viruses, toxins, and immunosuppressive particles, and is positioned to address what the company terms “the largest opportunity in infectious disease,” the treatment of drug and vaccine resistant viruses.